- Research article
- Open Access
Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer
© Henrique et al.; licensee BioMed Central Ltd. 2013
- Received: 19 April 2013
- Accepted: 11 December 2013
- Published: 17 December 2013
Multidrug resistance 1 (MDR1) gene encodes for an ATP binding cassette transporter - P-glycoprotein (P-gp) - involved in chemoresistance to taxanes. MDR1 promoter methylation is frequent in prostate carcinoma (PCa), suggesting an epigenetic regulation but no functional correlation has been established. We aimed to elucidate the epigenetic mechanisms involved in MDR1 deregulation in PCa.
MDR1 promoter methylation and P-gp expression were assessed in 121 PCa, 39 high-grade prostatic intraepithelial neoplasia (HGPIN), 28 benign prostatic hyperplasia (BPH) and 10 morphologically normal prostate tissue (NPT) samples, using quantitative methylation specific PCR and immunohistochemistry, respectively. PCa cell lines were exposed to a DNA methyltransferases inhibitor 5-aza-2′deoxycytidine (DAC) and histone deacetylases inhibitor trichostatin A (TSA). Methylation and histone posttranscriptional modifications status were characterized and correlated with mRNA and protein expression. MDR1 promoter methylation levels and frequency significantly increased from NPTs, to HGPIN and to PCa. Conversely, decreased or absent P-gp immunoexpression was observed in HGPIN and PCa, inversely correlating with methylation levels. Exposure to DAC alone did not alter significantly methylation levels, although increased expression was apparent. However, P-gp mRNA and protein re-expression were higher in cell lines exposed to TSA alone or combined with DAC. Accordingly, histone active marks H3Ac, H3K4me2, H3K4me3, H3K9Ac, and H4Ac were increased at the MDR1 promoter after exposure to TSA alone or combined with DAC.
Our data suggests that, in prostate carcinogenesis, MDR1 downregulation is mainly due to histone post-translational modifications. This occurs concomitantly with aberrant promoter methylation, substantiating the association with P-gp decreased expression.
- CpG island hypermethylation
- Epigenetic regulation
- Histone post-translational activation/repression marks
P-glycoprotein (P-gp), a membrane protein that acts as an ATP-binding cassette (ABC) transporter, is actively involved in the efflux of antineoplastic agents from cancer cells [1, 2]. Together with the other members of the ABC transporters family, it provides protection against xenobiotics and certain endogenous molecules, producing the multidrug resistance (MDR) phenotype, by which cancer cells become insensitive or unresponsive to a wide spectrum of drugs . This transporter is encoded by the MDR1/ABCB1 gene (multidrug resistance receptor 1/ ATP-binding cassette, sub-family B, member 1), mapped at 7q21, which is usually expressed in a limited number of tissues (gastrointestinal, liver, kidney and capillary endothelial cells in brain, ovary, and testis) . The MDR1 gene is composed by two promoters, a major downstream/proximal (DSP) and a minor upstream (USP), along with 28 exons [4–7]. In human cells, the DSP, which encompasses one CpG island, along with two other CpG islands (one located in exon 1 and the other in intron 1) regulates most of the transcriptional activity [4, 6–8]. Like other promoters, sequences downstream of the initiation site are also important for the overall transcription regulation  and it has been shown that MDR1 transcription might be modulated by proteins capable of modifying nucleosomal histones . Thus, epigenetic mechanisms are likely to play an important role in MDR1 expression regulation.
Remarkably, MDR1 promoter methylation is very frequent in prostate carcinoma (PCa) [11–13], which represents the second most frequent neoplasia among male population worldwide (13.6% of the total) and the fifth most common cancer overall , being the second leading cause of cancer-related death in men . This observation, in conjunction with the significantly lower levels of methylation observed in non-tumorous prostate tissues, has placed MDR1 in the restricted group of candidate epigenetic-based biomarkers specific for PCa . Because P-gp expression has been found to be generally lower in PCa than normal prostate glands [17, 18], cancer-associated aberrant promoter methylation has been postulated as the main mechanism underlying MDR1 silencing in PCa [11, 12]. However, functional evidence for that association has not been reported yet.
It is widely acknowledged that DNA methylation and other epigenetic mechanisms, such as histone modifications, act in concert to regulate gene expression through alterations in chromatin structure [19, 20]. Aberrant methylation of promoter CpG islands results in transcriptional silencing through several mechanisms, including the attraction of proteins that interact with histone deacetylases, and chromatin condensation, precluding the binding of transcriptional factors to the promoter, thus modulating gene expression and, consequently, tumour phenotype. As a result, the bulk of methylation in a tumour may reflect its biological and clinical behavior [19, 21]. Likewise, histone post-translational modifications are also strongly correlated with transcription regulation. Both positive (H3Ac; H3K4me2; H3K4me3; H3K9Ac; H4Ac) and negative-acting marks (H3K9me3; H3K27me3) are established across promoters during gene activation or gene repression, respectively, and the interplay of those histone modifications ultimately control gene expression . Importantly, the interplay between DNA methylation and histone modifications during gene silencing is currently acknowledged, as well as their importance in the integration of environmental and intrinsic stimuli in gene expression control.
Thus, we aimed to elucidate the role of epigenetic mechanisms in MDR1 deregulation in prostate carcinogenesis. For that purpose, MDR1 promoter methylation and P-gp expression was firstly assessed in a series of PCa, high grade prostatic intraepithelial neoplasia (HGPIN) – a precursor lesion of PCa – and non-tumorous prostate tissues [benign prostatic hyperplasia (BPH) and morphologically normal prostate tissue (NPT)]. Then, PCa cell lines were exposed to epigenetic modulating drugs and their effect on MDR1 promoter methylation and mRNA and protein expression was assessed. Finally, activating histone post-translational modifications associated with the MDR1 promoter region, prior and after exposure to epigenetic modulating drugs, were surveyed and correlated with gene expression status.
Clinical and pathological characteristics
Clinical and pathological characteristics of patient populations
Number of patients
Age, median (range)
PSA, ng/mL, median (range)
Gleason score, median (range)
Pathological stage (%)
MDR1 promoter methylation in prostatic tissue
Frequency of positive cases for MDR1 promoter methylation, distribution of methylation levels in normal prostate tissue and prostate lesions [Median (IQR: interquartile range)], and correlation with histopathological parameters
p < 0.001
p < 0.001
85.8 (36.6 - 192.0)
p = 0.142
p = 0.097
p < 0.001
p = 0.001
57.6 (29.4 - 158.2)
140.8 (37.6 - 227.7)
P-gp immunoexpression in prostatic tissues
P-gp immunoexpression in prostatic tissues
-0.702, p < 0.001
P-gp immunoexpression and MDR1 promoter methylation in prostate tissues
The distribution of MDR1 methylation levels in prostate tissues according to P-gp immunoexpression is graphically displayed in Figure 2. Statistical analysis demonstrated significant differences in methylation levels among immunoexpression groups 0 and 2+, and 1+ and 2+ (Mann–Whitney, Bonferroni-adjusted p < 0.001 for both), when all types of prostate tissue samples were considered. However, no statistically significant differences in MDR1 methylation levels were apparent between tumors scored 0 and 1+ for P-gp immunoexpression. Thus, the differences depicted between immunoexpression groups 0 and 1+, in the one hand, and group 2+, in the other, are mainly due to the inclusion of non-cancerous tissues, i.e., BPH and NPT in group 2+.
Methylation and expression analysis of MDR1 in PCa cell lines
To further assess whether MDR1 was epigenetically deregulated in PCa, the four cell lines were exposed to epigenetic modulating drugs and the results were analyzed either by bisulfite sequencing, qMSP or qRT-PCR.
Nevertheless, MDR1 expression levels increased in all cancer cell lines after treatment with epigenetic modulating drugs (Dunnet’s test, 0.001 ≤ p ≤ 0.015). Interestingly, re-expression levels were significantly higher when DAC and TSA were used in combination, in all cell lines (Dunnet’s test, p < 0.001) except for LNCaP, in which TSA alone induced the most impressive enhancement in MDR1 transcript levels (Dunnet’s test, p < 0.001).
Effect of epigenetic modulating drugs on activating histone marks at the MDR1 promoter in PCa cell lines
Because histone post-translational modifications are also associated with gene transcription activation/repression status, ChIP analysis was carried out for the native MDR1 promoter in LNCaP, DU145 and PC3 cell lines, after treatment with TSA alone or combined with DAC. Moreover, since the effect in MDR1 re-expression of DAC alone was modest, the histone marks were not assessed for this treatment regimen.
The P-glycoprotein, encoded by the MDR1/ABCB1 gene, is a transmembrane protein involved in ATP-dependent transport of specific substrates across lipid membranes, playing an important role in steroid metabolism and in the export of metabolites, carcinogens and cytotoxic drugs such as anthracyclines, taxanes, vinca alkaloids and epipodophyllotoxins [2, 4]. Although several mutations in this transporter have been associated with human disease, the actual consequences in its function are still controversial . In PCa, MDR1 is frequently methylated at its promoter region (an epigenetic event mostly associated with gene silencing) compared to non-tumorous prostate tissues and has thus been proposed as a PCa biomarker [11–13]. Although a few studies have correlated MDR1 promoter methylation with decreased transcription in PCa , the biologic impact of this epigenetic alteration and its role in prostate carcinogenesis has not been fully elucidated. Herein, we showed that although MDR1 promoter methylation is, indeed, a frequent event in PCa, occurring early in prostate carcinogenesis and it is associated with decreased mRNA and protein levels. However, promoter methylation does not seem to be prime cause of MDR1 silencing. Instead, our results indicate that post-translational histone modifications constitute the mechanism underlying MDR1 deregulation in PCa.
Promoter methylation of several cancer-related genes (e.g., GSTP1, APC, RARB2, and RASSF1A) has been extensively documented in PCa and seems to occur early in prostate carcinogenesis, as demonstrated by its intermediate frequency in HGPIN lesions . High frequency of MDR1 promoter methylation has been previously reported in PCa, ranging between 54% and 88% [11–13]. In our study, MDR1 methylation was found in 67.8% of the tumors, which is within the range of previous reports, as well as in 37.8% of HGPIN lesions. To the best of our knowledge, our study is the first to demonstrate MDR1 methylation in HGPIN lesions, which are precursors of prostate adenocarcinoma. Moreover, non-cancerous prostate tissues, including NPT and HBP, were scarcely methylated, in line with previous reports [11, 12]. Taken together, these results sustain that the progressive methylation of genes that play critical roles in controlling cell proliferation or differentiation, as well as protection of DNA from mutagens, constitutes an important mechanism not only in neoplastic transformation, but also in the process of tumor progression in the prostate. This postulate is further supported by the association between methylation levels of several of the aforementioned genes with tumor aggressiveness [23, 24]. Additionally, we found that MDR1 promoter methylation levels increased with pathological stage, in accordance with previous studies, which also disclosed an association with higher Gleason score , not found in our series. Thus, MDR1 seems to follow the same trend of other cancer-related genes in prostate carcinogenesis.
The association of aberrant promoter methylation with gene silencing has been demonstrated for several genes in many cancer models [16, 25, 26]. In this study, we found that the expression of P-gp, the protein encoded by MDR1, was inversely correlated with promoter methylation levels. Similar results were previously reported for PCa at protein  and transcript level . Thus, it seems reasonable to assume that aberrant CpG island methylation was responsible for MDR1 silencing in PCa. To test that hypothesis, we exposed four PCa cell lines to epigenetic modulating drugs, which are able to reverse DNA methylation and histone deacetylation. Surprisingly, increased expression of MDR1 mRNA was not associated with a decrease in methylation levels, but also the highest re-expression levels were observed when the demethylating agent was associated with the HDAC inhibitor. These results strongly suggested that histone modifications are more likely to be the main cause of MDR1 silencing in PCa. It could be argued that the concentration of DAC to which PCa cell lines were exposed was not sufficient to induce MDR1 demethylation. However, not only the same concentration is effective for inducing demethylation of other genes in PCa cell lines [28, 29] but also the use of TSA alone was able to increase MDR1 expression in our experiments. Nevertheless, MDR1 expression was more robustly up-regulated following exposure to both epigenetic modulating drugs. It might be questioned whether the analyzed region of the MDR1 gene is critical for regulation of expression. Nonetheless, it has been previously demonstrated that the CpG island analyzed in our study was involved in the regulation of MDR1 transcriptional activity [4, 6–8] and that it was densely methylated in PCa . Alternatively, the possibility that exposure to DAC and TSA leads to re-activation of genes which positively regulate MDR1 can not be dismissed.
To further investigate whether histone modification might be involved in MDR1 silencing in PCa, we compared histone active marks (H3Ac, H3K4me2, H3K4me3, H3K9Ac and H4Ac) at the MDR1 gene promoter, after exposure to TSA alone or in combination with DAC, compared to untreated cells. We found an overall enhancement in these active marks following exposure to TSA and/or DAC, in particular the H3K4me2 mark. Importantly, these findings were correlated, at protein level, with an increase in P-gp expression. Interestingly, enhancement of H3Ac at the MDR1 promoter has been previously correlated with gene activation in sarcoma cell lines . Thus, our results indicate that histone onco-modifications are likely to be the most important epigenetic event associated with MDR1 downregulation in PCa, although it is associated with dense CpG island methylation. There is some controversy regarding which epigenetic alteration arises first and how it relates to effective gene silencing. Remarkably, in PCa, histone onco-modifications herald CpG methylation in RASSF1A downregulation whereas the opposite occurs for GSTP1 inactivation [31, 32]. Although either scenario might fit our observations, the occurrence of promoter methylation early in prostate carcinogenesis (HGPIN) and the experimental gene re-expression observed following exposure to epigenetic modulating drugs without significant changes in promoter methylation levels, suggest that CpG methylation precedes histone onco-modifications.
MDR1 has been associated with the “multidrug resistance” phenotype . Thus, from a biological standpoint, it is almost counterintuitive that MDR1 gene silencing is associated with PCa development and progression as the loss of P-gp expression may be interpreted as an unfavorable change for neoplastic cells. However, even in other tumor models, P-pg expression was found to be higher in localized than in metastatic disease  also indicating a connection between P-gp loss of expression and tumor progression. This is also supported by the previous finding that MDR1 downregulation was associated with increased cell proliferation and unaltered apoptosis in PCa . Nevertheless, MDR1 silencing may also provide a therapeutic opportunity PCa treatment. Owing to the role of this protein in the removal of xenobiotics (e.g., taxanes, Vinca alkaloids) from the intracellular milieu/environment into urine and bile, thus promoting their elimination  decreased expression of P-gp is likely to increase the efficacy of chemotherapeutic agents for treatment of cancer patients. This assumption may be of clinical relevance, since castration-resistant PCa patients treated with regimens that include taxanes have improved survival rates . It is, then, tempting to speculate whether MDR1 promoter methylation and/or P-gp expression might constitute biomarkers predictive of response to taxane therapy in PCa patients.
In conclusion, we have shown that MDR1 aberrant promoter methylation and decreased expression are common events in PCa. These alterations seem to occur early in prostate carcinogenesis and promoter methylation is associated with clinicopathological features of tumor aggressiveness. Although MDR1 promoter methylation is inversely correlated with gene expression, effective MDR1 silencing is mostly likely due to histone onco-modifications, which may be heralded by CpG methylation at regulatory sites.
Patients and samples
Tissue samples of PCa were collected from 121 patients consecutively diagnosed and primarily treated with radical prostatectomy at Portuguese Oncology Institute – Porto. In 37 cases, a dominant HGPIN lesion was identified and collected for further analysis. BPH specimens were collected from 26 patients submitted to transurethral resection of the prostate and 10 NPT were procured from the peripheral zone of prostates that did not harbor PCa (obtained from cystoprostatectomy specimens of bladder cancer patients) and these were used as controls. All specimens were fresh-frozen at -80ºC and subsequently cut in a cryostat for microscopic evaluation and selection of areas for analysis. Cut sections were trimmed to maximize target cell content (>70%). From each specimen, parallel fragments were collected, formalin-fixed and paraffin-embedded for routine histopathological examination, including Gleason scoring  and pathological staging , by an expert pathologist. Relevant clinical data was collected from the clinical charts. This study and respective informed consent from was approved by the institutional review board [Comissão de Ética para a Saúde-(IRB-CES-IPOFG-EPE 019/08)] of Portuguese Oncology Institute - Porto, Portugal.
Cell culture and treatment with epigenetic modulating drugs
To assess the role of epigenetic mechanisms in MDR1 altered expression, representative PCa cell lines DU145 [obtained from the American Type Culture Collection (ATCC, Lockville, MD)], LNCaP and PC3 (kindly provided by Prof. Ragnhild A. Lothe from the Department of Cancer Prevention at The Institute for Cancer Research, Oslo, Norway) and 22Rv1 (kindly provided by Dr. David Sidransky at the Johns Hopkins University School of Medicine, Baltimore, MD, USA) were exposed to epigenetic modulating drugs. Cell lines were cultured according to the manufacturer’s specifications, with 10% fetal bovine serum (Gibco, USA) and antibiotics (100 units/mL penicillin G, and 100 μg/mL streptomycin, Gibco), in a humidified atmosphere of 5% CO2 at 37ºC. All PCa cell lines were karyotyped by G-banding (for validation purposes) and routinely tested for Mycoplasma spp. contamination (PCR Mycoplasma Detection Set, Clontech Laboratories, USA). The four cell lines were grown and treated with a pharmacologic inhibitor of DNA methyltransferases DAC (Sigma-Aldrich®, Germany) - 1 μM for 72 h - and/or a pan-inhibitor of histone deacetylases TSA (Sigma-Aldrich®, Germany) - 0.5 μM - added in the final 24 h. In parallel, the same cell lines were cultured without treatment for 72 hours and were harvested before confluence. The medium and the drugs were changed every 24 h. After 72 hours, cells were harvested, by tripsinization, for DNA and RNA extraction or fixed and scraped for Chromatin Immunoprecipitation (ChIP) assays. Protein extracts were also obtained using RIPA lysis buffer (Santa Cruz Biotechnology, CA, USA).
Isolation of nucleic acids and bisulfite treatment
DNA from prostate tissues and cell lines was extracted by the phenol-chloroform method, at pH 8, as described by Pearson et al.. Total RNA from tissue samples and cancer cell lines was isolated using Trizol (Invitrogen, USA). DNA and RNA concentrations were determined using a ND-1000 Nanodrop (NanoDrop Technologies, USA).
All DNA samples were submitted to sodium bisulfite modification, based on the previously described method [38, 39]. Briefly, 2 μg of genomic DNA from each sample were used for the chemical treatment. Bisulfite-modified DNA was purified using a vacuum manifold and a Wizard DNA Clean-up System [Promega Corporation, USA], treated again with sodium hydroxide, precipitated with ethanol, eluted in 120 μl of water and stored at -80ºC.
Bisulfite modified DNA from three different PCa cell lines (LNCaP, DU145 and PC3), exposed to DAC and/or TSA as abovementioned, was used to evaluate the methylation status of CG dinucleotides, by bisulfite sequencing using primers for a specific sequence of MDR1 promoter, addressing the same region that was further analyzed by qMSP . The protocol was performed as described elsewhere . PCR reactions for direct included a 10-minute 94ºC denaturation step followed by 40 cycles of 94ºC for 30 seconds, annealing temperature for 30 seconds, and 72ºC for 30 seconds. PCR products were loaded onto a nondenaturing 2% agarose gels, stained with ethidium bromide and visualized under an ultraviolet transilluminator. Excess primer and nucleotides were removed by Illustra GFX PCR DNA and Gel Band Purification kit (GE Healthcare, USB Corporation, Cleveland, OH) following the protocol of the manufacturer. The purified products were sequenced using the dGTP BigDye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems) in an ABI PRISMTM 310 Genetic Analyzer (Applied Biosystems). The approximate amount of methyl cytosine of each CpG site was calculated by comparing the peak height of the cytosine signal with the sum of the cytosine and thymine peak height signals . CpG sites with ratio ranges 0–0.20, 0.21-0.80, and 0.81-1.0 were considered unmethylated, partially methylated, and fully methylated, respectively.
Quantitative methylation-specific PCR (qMSP)
The modified DNA was used as a template for real-time fluorogenic qMSP. All samples were subjected to two reactions of amplification, one for the quantification of methylated MDR1 and the other for quantification of an internal reference gene (β-actin) using primers and probes reported elsewhere [11, 23]. The converted DNA, positive and negative controls, and commercial standards with serial dilutions of fully methylated DNA were amplified in the same run. These standards were used to construct a calibration curve in order to quantify the fully methylated genes in the two reactions. Fluorogenic qMSP assays were carried out in an Applied Biosystems 7000 Sequence Detector (Applied Biosystems, USA). PCR was performed in separate wells for each primer/probe set and each sample was run in triplicate. The final reaction mixture consisted of 600 nM of each primer (Invitrogen, USA); 200 nM probe (Applied Biosystems, USA); 0.75 unit of platinum Taq polymerase (Invitrogen, USA); 200 μM each of dATP, dCTP, dGTP, and dTTP; 16.6 mM ammonium sulfate; 67 mM Trizma; 6.7 mM magnesium chloride; 10 mM mercaptoethanol; 0.1% DMSO, and 3 μL bisulfite-converted genomic DNA. PCR was performed using the following conditions: 95ºC for 2 min, followed by 50 cycles at 95ºC for 15 s and 60ºC for 1 min. For each sample, the relative level of methylation in MDR1 promoter was obtained by dividing the value of methylated MDR1 by the respective value of β-actin, which was then multiplied by 1000 for easier tabulation.
Quantitative reverse-transcription PCR (RT-qPCR)
Total RNA from all PCa cancer cell lines untreated, treated either with 1 μM of DAC for 72 hours, or treated with the combination of 1 μM of DAC (72 h) and 0.5 μM of TSA (added in the last 12 h) was analyzed. From each sample, 0.5 μg of total RNA was transcribed into cDNA by reverse transcription using the RevertAidTM H Minus First Strand cDNA Synthesis Kit (Fermentas, Canada), including random hexamer primers. The cDNA was used as the template for the real-time quantitative PCR reaction. MDR1 (Hs01070651_m1, Applied Biosystems, USA), and the endogenous control assay GUSB (Hs99999908_m1, Applied Biosystems, USA) were amplified separately in 96-well plates following the recommended protocol (Applied Biosystems, USA), and the real time quantitative gene expression was measured by the 7500 Real-Time PCR System (Applied Biosystems, USA). All samples were analyzed in triplicate, and the mean value was used for data analysis. The human universal reference RNA (Stratagene, USA) was used to generate a standard curve on each plate, and the resulting quantitative expression levels of the tested gene were normalized against the mean value of the endogenous control to obtain a ratio that was then multiplied by 1000 for easier tabulation.
Immunohistochemistry was performed according to the avidin-biotin method using the VECTASTAIN® Universal Elite ABC Kit [©Vector Laboratories, USA]. Sections (3 μm thick) from paraffin-embedded tissues, corresponding to the samples used for methylation analysis, were deparaffinised in xylene and hydrated through a graded alcohol series. Antigen retrieval was accomplished by microwaving the specimens at 800 W for 5 minutes in EDTA buffer. After cooling the slides, endogenous peroxidase activity was blocked by incubating the sections in hydrogen peroxide in 3% methanol for 30 minutes. The sections were treated with 5% normal horse serum in 1% PBS-BSA for 30 minutes to reduce background interference. The primary mouse monoclonal antibody (C494 clone, Thermo Scientific, UK) was applied in 1:50 dilution with 1% PBS-BSA and left at 4ºC overnight. The secondary biotinylated horse antibody at a dilution of 1:50 was added for 30 minutes. To enhance the immunohistochemical staining, sections were incubated in avidin-biotin complexes for 30 minutes. Then, 3,3′-diaminobenzidine (Sigma-Aldrich®, Germany) was used for visualization and hematoxilin for nuclear counterstaing. Finally, after dehydration and diaphanization, slides were mounted in Entellan® (Merck-Millipore, Germany). Adrenal gland tissue sections showing intense immunoreactivity for P-gp, were used as positive controls. The negative control consisted on the omission of the primary antibody. Assessment of antibody expression was performed by a pathologist (RH) blinded to molecular analyses data. Imunohistochemistry results were categorized according to stain intensity as 2+ (expression similar to normal prostate tissue), 1+ (expression lower than that of normal prostate tissue), and 0 (no immunoexpression).
Chromatin immunoprecipitation (ChIP) Assay
EZ-Magna ChIP™ G-Chromatin Immunoprecipitation Kit and the Magna Grip™ Rack (Merck-Millipore, Germany) were used to perform ChIP assay according to the manufacturer’s instruction. For each chromatin immunoprecipitation, 5 μg of anti-AcH3 (06–599, Millipore, USA), anti-H3K4me2 (ab32356, Abcam, UK), anti-H3K4me3 (ab8580, Abcam, UK), anti-AcH3K9 (17–658, Millipore, USA), anti-AcH4 (06–866, Millipore, USA) and 1 μL of the negative control provided with the kit (normal mouse IgG) were used. Quantification of DNA was performed in a 7000 Real-Time PCR System (Applied Biosystems, USA), using Power SYBR® Green PCR Master Mix (Applied Biosystems, USA) and gene-specific primers for gene promoter of MDR1 – sense: 5′-AGTCATCTGTGGTGAGGCTGAT-3′; anti-sense: 5′-TACTCGAATGAGCTCAGGCTTC-3′ [≈ 800 bp upstream Transcription Start Site (TSS)]. The relative amount of promoter DNA was normalized using Input Percent Method.
For mock and treated LNCaP, DU145 and PC3 cell lines, protein extract concentrations were determined using Pierce® BCA Protein Assay Kit (Thermo Scientific, Inc., Bremen, Germany). Subsequently, 30 μg of total protein were loaded in each well, and separated by SDS-PAGE, transferred to nitrocellulose membranes and probed with antibodies against P-glycoprotein (Abcam, ab129450 at 1:1000) or the endogenous control β-actin (Sigma-Aldrich, A1978 at 1:10000). Secondary antibodies, conjugated with horseradish peroxidase, were incubated at a dilution of 1:3000. Finally, blots were developed using Immun-Star™ WesternC™ Kit according to manufacturer’s indications (BioRad, Hercules, CA, USA) and exposed to Amersham Hyperfilm (GE Healthcare). Experiments were done with biological triplicates. Relative optical density determination was performed using QuantityOne® Software version 4.6.6. (Biorad, Hercules, CA, USA).
As the analyzed variables did not follow a normal distribution, nonparametric tests were used. In each group of samples, frequencies of MDR1 methylation were compared using the Chi-square test for trend. Median and interquartile range (p25-p75) of MDR1 methylation levels were also determined, and then compared using Kruskall-Wallis test or the Mann–Whitney U-test, depending on the number of categories in each group. Likewise, the relationship between methylation ratios and standard clinicopathological variables (age, serum PSA levels, tumor grade and stage), were evaluated using the Kruskall-Wallis or Mann–Whitney tests. A Spearman nonparametric correlation test was additionally performed to compare age and methylation levels.
Frequencies of immunoexpression along sample groups were compared using the Chi-square test, and the directional measure Somers’d was additionally computed. Somers’ statistic varies from -1 to 1 and assesses the association between two ordinal variables, with a value of 1 indicating a strong positive association, and a value of -1 indicating a strong negative one. The correlation between MDR1 promoter methylation levels and P-gp immunoexpression was assessed using the Kruskall-Wallis test, followed by Mann–Whitney U-tests. For this analysis, all sample types were considered within the same group of immunoexpression score.
In cell lines, differences in transcript and methylation levels between treatments were determined using One-Way Analysis of Variance (one-Way ANOVA) test, followed by a multiple comparisons Dunnet’s test, comparing all groups against the Mock. Differences regarding protein levels were also evaluated using a one-Way ANOVA test, followed by a multiple comparison Dunnet’s test, comparing all groups against the experimental control.
All tests were two-sided and p-values were considered significant when inferior to 0.05. For multiple comparisons the Bonferroni method was used to adjust for p values. Statistical analyses were performed using a computer-assisted program (SPSS version 20.0, USA).
The authors thank Franclim Ricardo Ribeiro for statistical advice and Inês Moura, Irene Pais and Mafalda Almeida for their technical support. This publication was supported in part by grant CI-IPOP-4-2008 from Research Center of Portuguese Oncology Institute Porto. Additional funds were provided by a grant from the European Community’s Seventh Framework Programme – Grant number FP7-HEALTH-F5-2009-241783 (AIO and CJ).
- Shukla S, Ohnuma S, Ambudkar SV: Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets. 2011, 12 (5): 621-630. 10.2174/138945011795378540.PubMed CentralView ArticlePubMedGoogle Scholar
- Schinkel AH, Jonker JW: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003, 55 (1): 3-29. 10.1016/S0169-409X(02)00169-2.View ArticlePubMedGoogle Scholar
- Tiwari AK, Sodani K, Dai CL, Ashby CR, Chen ZS: Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol. 2011, 12 (4): 570-594. 10.2174/138920111795164048.View ArticlePubMedGoogle Scholar
- Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM: P-glycoprotein: from genomics to mechanism. Oncogene. 2003, 22 (47): 7468-7485. 10.1038/sj.onc.1206948.View ArticlePubMedGoogle Scholar
- Ueda K, Pastan I, Gottesman MM: Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem. 1987, 262 (36): 17432-17436.PubMedGoogle Scholar
- Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB: Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem. 1990, 265 (1): 506-514.PubMedGoogle Scholar
- Chen GK, Sale S, Tan T, Ermoian RP, Sikic BI: CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. Mol Pharmacol. 2004, 65 (4): 906-916. 10.1124/mol.65.4.906.View ArticlePubMedGoogle Scholar
- Baker EK, El-Osta A: Epigenetic regulation of multidrug resistance 1 gene expression: profiling CpG methylation status using bisulphite sequencing. Methods Mol Biol. 2010, 596: 183-198. 10.1007/978-1-60761-416-6_9.View ArticlePubMedGoogle Scholar
- Cornwell MM: The human multidrug resistance gene: sequences upstream and downstream of the initiation site influence transcription. Cell Growth Differ. 1990, 1 (12): 607-615.PubMedGoogle Scholar
- Jin S, Scotto KW: Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol. 1998, 18 (7): 4377-4384.PubMed CentralView ArticlePubMedGoogle Scholar
- Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW, Anast JW, Li LC, Urakami S, Terashima M, et al: CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res. 2004, 64 (17): 5956-5962. 10.1158/0008-5472.CAN-04-0081.View ArticlePubMedGoogle Scholar
- Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, et al: Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res. 2005, 11 (18): 6582-6588. 10.1158/1078-0432.CCR-05-0658.View ArticlePubMedGoogle Scholar
- Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004, 64 (6): 1975-1986. 10.1158/0008-5472.CAN-03-3972.View ArticlePubMedGoogle Scholar
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127 (12): 2893-2917. 10.1002/ijc.25516.View ArticlePubMedGoogle Scholar
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107.View ArticlePubMedGoogle Scholar
- Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG, Shariat SF: Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol. 2011, 60 (4): 753-766. 10.1016/j.eururo.2011.06.035.View ArticlePubMedGoogle Scholar
- Bhangal G, Halford S, Wang J, Roylance R, Shah R, Waxman J: Expression of the multidrug resistance gene in human prostate cancer. Urol Oncol. 2000, 5 (3): 118-121. 10.1016/S1078-1439(99)00055-1.View ArticlePubMedGoogle Scholar
- Kawai K, Sakurai M, Sakai T, Misaki M, Kusano I, Shiraishi T, Yatani R: Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies. Cancer Lett. 2000, 150 (2): 147-153. 10.1016/S0304-3835(99)00384-5.View ArticlePubMedGoogle Scholar
- Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007, 8 (4): 286-298. 10.1038/nrg2005.View ArticlePubMedGoogle Scholar
- Sandoval J, Esteller M: Cancer epigenomics: beyond genomics. Curr Opin Genet Dev. 2012, 22 (1): 50-55. 10.1016/j.gde.2012.02.008.View ArticlePubMedGoogle Scholar
- Dobosy JR, Roberts JL, Fu VX, Jarrard DF: The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol. 2007, 177 (3): 822-831. 10.1016/j.juro.2006.10.063.View ArticlePubMedGoogle Scholar
- Berger SL: The complex language of chromatin regulation during transcription. Nature. 2007, 447 (7143): 407-412. 10.1038/nature05915.View ArticlePubMedGoogle Scholar
- Jeronimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D, Teixeira MR, Lopes C, Sidransky D: Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res. 2004, 10 (12 Pt 1): 4010-4014.View ArticlePubMedGoogle Scholar
- Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D: A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res. 2004, 10 (24): 8472-8478. 10.1158/1078-0432.CCR-04-0894.View ArticlePubMedGoogle Scholar
- Tsai HC, Baylin SB: Cancer epigenetics: linking basic biology to clinical medicine. Cell Res. 2011, 21 (3): 502-517. 10.1038/cr.2011.24.PubMed CentralView ArticlePubMedGoogle Scholar
- Heyn H, Esteller M: DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet. 2012, 13 (10): 679-692. 10.1038/nrg3270.View ArticlePubMedGoogle Scholar
- Van Brussel JP, Jan Van Steenbrugge G, Van Krimpen C, Bogdanowicz JF, Van Der Kwast TH, Schroder FH, Mickisch GH: Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol. 2001, 165 (1): 130-135. 10.1097/00005392-200101000-00032.View ArticlePubMedGoogle Scholar
- Henrique R, Costa VL, Cerveira N, Carvalho AL, Hoque MO, Ribeiro FR, Oliveira J, Teixeira MR, Sidransky D, Jeronimo C: Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl). 2006, 84 (11): 911-918. 10.1007/s00109-006-0099-4.View ArticleGoogle Scholar
- Costa VL, Henrique R, Danielsen SA, Eknaes M, Patricio P, Morais A, Oliveira J, Lothe RA, Teixeira MR, Lind GE, et al: TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics. 2011, 6 (9): 1120-1130. 10.4161/epi.6.9.16376.View ArticlePubMedGoogle Scholar
- Chen KG, Wang YC, Schaner ME, Francisco B, Duran GE, Juric D, Huff LM, Padilla-Nash H, Ried T, Fojo T, et al: Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. Cancer Res. 2005, 65 (20): 9388-9397. 10.1158/0008-5472.CAN-04-4133.View ArticlePubMedGoogle Scholar
- Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H, Kikuno N, Kawakami T, Tanaka Y, Pookot D, Chen Z, et al: Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res. 2007, 13 (9): 2541-2548. 10.1158/1078-0432.CCR-06-2225.View ArticlePubMedGoogle Scholar
- Okino ST, Pookot D, Majid S, Zhao H, Li LC, Place RF, Dahiya R: Chromatin changes on the GSTP1 promoter associated with its inactivation in prostate cancer. Mol Carcinog. 2007, 46 (10): 839-846. 10.1002/mc.20313.View ArticlePubMedGoogle Scholar
- Scotlandi K, Manara MC, Serra M, Benini S, Maurici D, Caputo A, De Giovanni C, Lollini PL, Nanni P, Picci P, et al: The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene. 1999, 18 (3): 739-746. 10.1038/sj.onc.1202330.View ArticlePubMedGoogle Scholar
- Mackler NJ, Pienta KJ: Drug insight: use of docetaxel in prostate and urothelial cancers. Nat Clin Pract Urol. 2005, 2 (2): 92–-100. quiz 101 p following 112View ArticlePubMedGoogle Scholar
- Epstein JI: An update of the Gleason grading system. J Urol. 2010, 183 (2): 433-440. 10.1016/j.juro.2009.10.046.View ArticlePubMedGoogle Scholar
- Eble J, Sauter G, Epstein JI, Sesterhenn IA: World Health Organization and International Agency for Research on Cancer: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. 2004, IARC: LyonGoogle Scholar
- Pearson HSD: DNA extraction from tissue. Methods Mol Biol. 2003, 226: 233-224.Google Scholar
- Clark SJ, Statham A, Stirzaker C, Molloy PL, Frommer M: DNA methylation: bisulphite modification and analysis. Nat Potoc. 2006, 1: 2353-2364.View ArticleGoogle Scholar
- Olek A, Oswald J, Walter J: A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res. 1996, 24 (24): 5064-5066. 10.1093/nar/24.24.5064.PubMed CentralView ArticlePubMedGoogle Scholar
- Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI, Rodrigues A, Magalhaes JS, Oliveira J, Lothe RA, et al: Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res. 2010, 16 (23): 5842-5851. 10.1158/1078-0432.CCR-10-1312.View ArticlePubMedGoogle Scholar
- Melki JR, Vincent PC, Clark SJ: Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 1999, 59 (15): 3730-3740.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.